DelveInsight’s, “Postoperative Pain Pipeline Insight, 2023,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Postoperative Pain Emerging Drugs, the Postoperative Pain pipeline analysis report provides a 360° view of the Postoperative Pain pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Postoperative Pain pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Postoperative Pain Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Postoperative Pain clinical trials studies, Postoperative Pain NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Postoperative Pain Pipeline Report
- Over 55+ Postoperative Pain companies are evaluating 55+ Postoperative Pain pipeline therapies in various stages of development, and their anticipated acceptance in the Postoperative Pain market would significantly increase market revenue.
- The leading Postoperative Pain Companies includes Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, Heron Therapeutics, Endo Pharmaceuticals, Mylan, Camurus, PainReform, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Nuance Biotech Co, PharmaTher, TSRL, Neumentum Inc., Janssen Pharmaceutica NV, McNeil Consumer Pharmaceuticals Co, and others.
- Promising Postoperative Pain Pipeline Therapies includes VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others.
- The Postoperative Pain companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The Postoperative Pain pipeline therapies under development are focused on novel approaches to treat/improve Postoperative Pain.
To explore more information on the latest breakthroughs in the Postoperative Pain Pipeline treatment landscape of the report, click here @ Postoperative Pain Pipeline Outlook
Postoperative Pain Overview
Postoperative Pain (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
Latest Developmental Activities in the Postoperative Pain Treatment Landscape
- In June 2021, Formosa Pharmaceuticals and China Grand Pharma announced that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and Macau. APP13007, derived from Formosa’s proprietary nanoparticle formulation platform, is a novel ophthalmic application of one of the most potent known corticosteroids for the treatment of inflammation and pain after cataract surgery.
- In October 2021, Neumentum entered into a license agreement with Nuance Biotech Co. Ltd, a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China.
- In January 2021, IACTA Pharmaceuticals, Inc. and Pharmaleads announced they that have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads' Dual Enkephalinase Inhibitors (DENKI®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.
- In June 2021, PharmaTher and TSRL entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs. PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.
- In November 2018, The Food and Drug Administration (FDA) announced fast track status for VVZ-149 (Vivozon Inc), a non-opioid, non-NSAID analgesic for the treatment of pain.
- In September 2018, Concentric Analgesics announced that it had received Breakthrough Therapy designation from the US FDA for CA-008 in post-surgical pain.
- In October 2019, Neumentum Inc. announced that it has entered into a global licensing agreement with Janssen Pharmaceutica NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies, for the rights to a novel oral analgesic, JNJ-10450232, plus a portfolio of backup compounds. Neumentum wants to take JNJ-10450232, which it describes as neither an opioid nor a nonsteroidal anti-inflammatory drug, forward in the treatment of moderate to moderately severe acute pain. The deal, financial details of which were not disclosed. The agreement covers an asset that came through a Phase II pain trial in 2015 only to stall following the completion of the study.
For further information, refer to the detailed Postoperative Pain Unmet Needs, Postoperative Pain Market Drivers, and Postoperative Pain Market Barriers, click here for Postoperative Pain Ongoing Clinical Trial Analysis
Postoperative Pain Emerging Drugs Profile
VVZ-149: Vivozon
VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating the robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons.
Qutenza: Grunenthal
Qutenza (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. It is currently in Phase III stage of development for the treatment of Post-surgical neuropathic pain.
CYT-1010: Cytogel Pharma
CYT-1010® is the first member of a new class of drugs, the endomorphins, to reach clinical development. It produces pain relief through a novel mechanism of action on the endomorphin (EM) receptor. CYT-1010, is entering Phase II clinical development, following a successful Phase I study in humans. This breakthrough pain medicine has shown reduced potential for addiction and significantly less risk of respiratory depression, relative to treatment with traditional pain medicines.
ACP-044: ACADIA Pharmaceuticals
ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. A Phase II study was initiated evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in March 2021.
CAM2048: Camurus
CAM2048 is a buprenorphine depot formulation for the treatment of postoperative pain providing rapid onset of action and therapeutic buprenorphine plasma levels over a couple of days. CAM2048 is being developed in collaboration with Braeburn Pharmaceuticals and has been successfully evaluated in a completed Phase I trial. The drug is currently being evaluated in Phase I/II stage of development.
ST 2427: SiteOne Therapeutics
ST-2427 is an experimental intravenous, non-opioid analgesic for the management of moderate-to-serve severe pain. ST-2427 blocks sodium ion channel 1.7 (NaV1.7). NaV1.7 is a type of sodium channel that is highly expressed in peripheral nerve fibers that play a critical role in the generation and conduction of pain signals. As ST-2427 does not enter the brain, it is not expected to cause the central nervous system adverse effects (e.g. sedation, nausea, dependence and addition) that plague existing pain therapeutics such as the opioids. The development of ST-2427 was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) under Award Number UG3DA049599.
Postoperative Pain Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. Phase III include, Vivozon.
Request a sample and discover the recent advances in Postoperative Pain Ongoing Clinical Trial Analysis and Medications, click here @ Postoperative Pain Treatment Landscape
Scope of the Postoperative Pain Pipeline Report
- Coverage- Global
- Postoperative Pain Companies- Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, Heron Therapeutics, Endo Pharmaceuticals, Mylan, Camurus, PainReform, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Nuance Biotech Co, PharmaTher, TSRL, Neumentum Inc., Janssen Pharmaceutica NV, McNeil Consumer Pharmaceuticals Co, and others.
- Postoperative Pain Pipeline Therapies- VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others.
- Postoperative Pain Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Postoperative Pain Market Drivers and Postoperative Pain Market Barriers, click here @ Postoperative Pain Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Postoperative Pain: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Postoperative Pain – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Postoperative Pain Collaboration Deals
- Late Stage Products (Phase III)
- VVZ-149: Vivozon
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TLC590: Taiwan Liposome Company
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ST 2427: SiteOne Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- INSB200: InSitu Biologics
- Drug profiles in the detailed report…..
- Inactive Products
- Postoperative Pain Key Companies
- Postoperative Pain Key Products
- Postoperative Pain- Unmet Needs
- Postoperative Pain- Market Drivers and Barriers
- Postoperative Pain- Future Perspectives and Conclusion
- Postoperative Pain Analyst Views
- Postoperative Pain Key Companies
- Appendix
Got Queries? Find out the related information on Postoperative Pain Mergers and acquisitions, Postoperative Pain Licensing Activities @ Postoperative Pain Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
